3R Research Foundation Switzerland - Front page
Projects


 

de | fr | en   print view

List of projects

141-14In-vitro alternatives to in-vivo bioconcentration-testing in fish: restricted to rainbow trout or broadly applicable ?
Segner, H., Prof., Centre for Fish and Wildlife Health, Vetsuisse Faculty, University of Bern, Switzerland
 
140-14Hydrocephalus simulator for testing of active ventriculoperitoneal shunts
Schmid Daners, M., Dr., Institute for Dynamic Systems and Control, Department of Mechanical and Process Engineering, ETH Zurich, Switzerland
 
139-14An in-vitro microvascular model of the endothelial barrier
Herrmann, M., Dr., AO Research Institute Davos, Switzerland
 
138-13Optimization of the nerve-cell-mimicking liposome assay as an in-vitro alternative for the detection of Clostridium-botulinum neurotoxins and for a validation of their presence in complex sample materials
Avondet, M.-A., Toxinology Group, Spiez Laboratory, Switzerland
 
137-13Validation of a new human in-vitro model of microglia
Filgueira, L., Prof., Department of Medicine, University of Fribourg, Switzerland
 
136-13Development of an in-vitro potency assay for the Clostridium chauvoei vaccines: Replacement of the guinea-pig-challenge potency test
Frey, J., Prof., Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Bern, Switzerland
 
135-13In-vitro engineering of a human cell-based threedimensional dynamic model of atherosclerosis
Weber, B, Dr. Dr., Swiss Center for Regenerative Medicine, University Hospital Zurich, Switzerland
 
134-12Cardiovascular simulator with autoregulation
Vandenberghe S,, Prof., ARTORG Center for Biomedical Research, University of Bern, Switzerland
 
133-12Development of an in vitro system to grow and investigate vascular endothelial cells under physiological flow conditions
Rieben R., Prof., Department of Clinical Research, University of Bern, Switzerland
 
132-12Identification of predictive in vitro markers of hematopoietic stem cell function
Lutolf M. P., Prof., Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
 
131-12Antibody phage selection strategy for application in non-specialized laboratories
Heinis Ch., Prof., Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland
 
130-11Establishment of an in-vitro organ-slice defect model for meniscal repair in orthopaedic research
Hunziker E., Prof., Center of Regenerative Medicine for Skeletal Tissues, University of Bern, Switzerland
 
129-11The use of microfluidic chambers to study axonal transport in PTEN and SOCS3 dependent axonal regeneration
He Zhigang, Prof., Children's Hospital and Department of Neurology, Harvard Medical School, Boston, MA 02115
 
128-11Genetic modification of the human airway epithelium – a paradigmatic system to study host responses to human respiratory viruses
Thiel V., PD Dr., Institut für Immunbiologie, Kantonsspital St. Gallen, Switzerland
 
127-11Establishing a novel system for quantitative production of murine basophils in vitro
Kaufmann T., PD Dr., Institute of Pharmacology, University of Bern, Switzerland
 
126-11Development and validation of a model to investigate myeloid-cell homeostasis
Benarafa C., Dr., Theodor Kocher Institute, University of Bern, Switzerland
 
125-11Nerve-cell mimicking liposomes as in vitro alternative to potency-testing of toxins with multistep pathways, such as Botulinum neurotoxins
Weingart O.G., Dr., Institute for Food, Nutrition and Health (IFNH), ETH Zurich, Switzerland;
 
124-10Comparative in vitro and in vivo testing on biofilm formation on the surface of bone grafts
Clauss M., Dr., Kantonsspital Liestal, Orthopädie, Liestal, Switzerland
 
123-10Use of "moribund" stage in the acute fish toxicity test according to OECD guideline 203 and its effect on LC50 values
Rufli H., Dr., ecotoxsolution, Basel, Switzerland
 
122-10Improved perioperative analgesia and reduced stress during recovery for the experimental animal: ultrasound-guided sciatic and femoral nerve block in sheep and quantitative assessment of block quality
Rohrbach H., Dr, Institute for Anaesthesiology and Pain Therapy, Vetsuisse Faculty, University of Bern, Switzerland
 
121-10Organotypic spinal cord slices to study SCI and MS like lesions
Chrast R., Prof. Dr., Department of Medical Genetics, University of Lausanne, Switzerland
 
120-10Development of non-invasive strategies to study corticospinal neuron disease, injury and repair
Jabaudon D., Prof. Dr., Dpt. of Basic Neurosciences, University of Geneva, Switzerland
 
119-10Non invasive electrical monitoring of the population spiking activity in the central nervous system
Gonzalez Andino S.L., Dr., University of Geneva and Geneva University Hospital, Switzerland
 
118-10Engineering of an in vitro hepatocyte tissue system for malaria liver infection research
Mancama D., Dr., Systems Biology, Biosciences Unit, CSIR, South Africa
 
117-09Embryonic stem-cell-derived in-vitro model of tissue inflammation following confrontation with implant materials
Wartenberg M., Prof. Dr., Friedrich Schiller University Jena and Justus Liebig University Giessen, Germany
 
116-09Organotypic brain-slice cultures derived from regularly-slaughtered animals as an in-vitro alternative for the investigation of neuroinfectious diseases in ruminants
Oevermann A., Dr., Vetsuisse Faculty, University of Berne, Switzerland
 
115-09Engineering of a human brain tumour model to replace animal experimentation
Preynat-Seauve O., Dr., University of Geneva, Switzerland
 
114-08Reduction of the number of animals used in the Fish Acute Toxicity Test
Rufli H., Dr., ecotoxsolution, Basel, Switzerland
 
113-08Generic in-vitro evaluation assay for immunological correlates of protection to replace animal challenge infections
Summerfield A., Dr., Institute of Virology and Immunoprophylaxis (IVI), Mittelhaeusern, Switzerland
 
112-08A novel in-vitro model for the holistic assessment and optimisation of engineered tissue for functional cartilage repair
Luo Z., Dr., Leeds Dental Institute, Leeds LS9 9LU, UK
 
111-08Establishment of an organ ex-vivo tissue slice model for cardiovascular research in particular for therapeutic atherosclerosis targeting
Hunziker P., PD Dr., Intensive Care Unit, University Hospital Basel, Switzerland
 
110-08Development of an in-vitro assay for the screening of antischistosomal drugs
Keiser J., Prof. Dr., Swiss Tropical Institute, University of Basel,Switzerland
 
109-08Evaluation of lipid fractions for the substitution of serum in cell culture media
Honegger P., Prof. Dr., Département de Physiologie, Université de Lausanne, Switzerland
 
108-07Cultured piscine hepatocytes as an in-vitro source of metabolic clearance data that is currently gleaned by in-vivo bioaccumulation testing in fish
Segner H., Prof. Dr., Centre for Fish and Wildlife Health, Vetsuisse Faculty, University of Berne, Switzerland
 
107-07Evaluation of an in vitro model to identify host parameters associated with virulence of Toxoplasma gondii strains
D’Souza S., Dr., Pasteur Institute of Brussels-ISP,1180-Uccle, Belgium
 
106-07Standardization and Pre-validation of MucilAir: A novel in vitro cell model of the human airway epithelium for testing acute and chronic effects of chemical compounds
Huang S., Dr., Epithelix Sàrl, Plan-les-Ouates, Geneva, Switzerland
 
105-06Establishment of an in vitro system for the prediction of the degree of virulence of classical swine fever virus isolates
Ruggli N., Dr., Institute of Virology and Immunoprophylaxis (IVI), Mittelhaeusern, Switzerland
 
104-06Development of in vitro strategies to propagate and characterize hemotrophic mycoplasmas
Hofmann-Lehmann R., Prof. Dr., Clinical Laboratory, Vetsuisse-Faculty, University of Zurich, Switzerland
 
103-06An in vitro Model of Central Nervous System Infection and Regeneration: Neuronal Stem Cells as Targets of Brain Damage & Regenerative Therapies in Bacterial Meningitis.
Leib S.L., Prof. Dr., Institute of Infectious Diseases, University of Bern, Switzerland
 
102-06Isolated, autologous blood-perfused heart: Replacement of heterotopic heart transplantation
Bogdanova A, Dr., Institute of Veterinary Physiology, University of Zurich, Switzerland
 
101-06Organotypic CNS slice cultures as an in-vitro model for immune mediated tissue damage and repair in multiple sclerosis
Goebels N., Prof. Dr., Heinrich-Heine University Düsseldorf Medical Faculty, Department of Neurology
 
100-06Development of an in-vitro system for modeling bioaccumulation of neutral, ionizable, and metabolically active organic pollutants in fish
Escher B., Prof. Dr., Dept. of Environmental Toxicology, EAWAG, Dübendorf, Switzerland
 
99-05The NEMO network (Non-mammalian Experimental Models for the study of bacterial infections)
Cosson P., Prof. Dr., Département de Physiologie Cellulaire et Métabolisme, Centre Medical Universitaire Genève, Geneva 4, Switzerland
 
98-05Establishment of a murine syngeneic co-culture system of intestinal epithelial cells with intraepithelial T lymphocyte subsets.
Mueller Ch., Prof. Dr., Institute of Pathology, University of Bern, Switzerland
 
97-05Development of a three-dimensional enteric cell culture model for in vitro studies of the intestinal eukaryotic parasites Cryptosporidium spp.
Mathis A., Prof. Dr., Institute of Parasitology, University of Zürich, Switzerland
 
96-05Assessment of pain and stress in mice by monitoring gene expression changes
Cinelli P., Dr., Institute of Laboratory Animal Science, University of Zurich, Switzerland
 
95-05Development of QSAR-Models for Classification and Prediction of Baseline Toxicity and of Uncoupling of Energy Transduction
Spycher S. + Escher B., Prof. Dr., Dept. of Environmental Toxicology, EAWAG, Dübendorf, Switzerland
 
94-04Tumor targeted reporter gene expression to improve and refine traditional models of Tumor growth and metastasis
Vorburger S., Dr., Department of Clinical Research, Visceral and Transplantation Surgery, University Hospital Bern, Switzerland
 
93-04Development of a novel multicellular 3-dimensional blood brain barrier in vitro model
Ogunshola O., Dr., Institute of Veterinary Physiology, Vetsuisse Faculty, University of Zürich, Switzerland
 
92-04Adjuvanticity of microbial-derived particles and synthetic analogs in vitro.
Padovan E., Prof. Dr., Instituto Gulbenkian de Ciência, Oerias, Portugal
 
91-04Establishment and validation of a Choroid Plexus Model to study drug transport
Fricker G., Prof. Dr., Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls Universität Heidelberg, Germany
 
90-03A non-mammalian system to study bacterial infections
Cosson P., Prof. Dr., Centre Medical Universitaire, Dpt de Morphologie, Geneva 4, Switzerland
 
89-03In vitro replica of the inner surface of the lungs, for the study of particle-cell interaction
Geiser Kamber M., Prof. Dr., Institute of Anatomy, University of Bern, Switzerland
 
88-03Assessing animal health and welfare and recognising pain and distress
Flecknell P., Prof. Dr., Comparative Biology Centre, University of Newcastle, UK
 
87-03Information on serum free cell lines, an interactive database
Strebel C., dipl. Ing. FH, CePower GmbH, Wädenswil, Switzerland
 
86-03Bone Formation in a loading chamber for ex-vivo bone culture
Richards R.G., Dr., AO Research Institute, Davos, Switzerland
 
85-03Development of an in vitro culture model to generate Neospora caninum and Toxoplasma gondii oocysts and sporozoites
Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland
 
84-02Direct cloning of human antibodies from purified specific B-cells
Wirthmueller U., Dr., Institute of Immunology, University Hospital Bern, Switzerland
 
83-02The development of an in vitro intervertebral disc organ culture system
Lee C., Dr., Biochemistry and Cell Biology Unit; AO Research Institute, Davos, Switzerland
 
82-02Magnetic Resonance Imaging (MRI) for the non-invasive assessment of lung inflammation and pulmonary function in the rat
Beckmann N., PD Dr., Novartis Pharma AG Basel Novartis Institute of Biomedical Research (NIBR), Basel, Switzerland
 
81-02In vitro model for the testing of endothelial cell activation and damage in whole blood
Rieben R., Prof. Dr., Heart Transplantation Laboratory, Cardiology, University Hospital Bern, Switzerland
 
80-01Induction of a primary T cell mediated immune response against drugs and drug metabolites in vitro
Pichler, W.J., Prof. Dr., Division Allergology, University Hospital Bern, Switzerland
 
79-01Screening methods for repellents and attachment deterrents for ticks in-vitro
Guerin P., PD Dr., Institute of Zoology, University of Neuchâtel, Switzerland
 
78-01Validation of a combined perfusion/loading chamber for ex-vivo bone metabolic studies and bone-biomaterial interactions
Richards R.G., Dr., AO Research Institute, Davos, Switzerland
 
77-01Reproducibility and external validity of findings from animal experiments: influence of housing conditions
Würbel H., Prof. Dr., Institute of Laboratory Animal Science, University of Zurich, Switzerland
 
76-01Development of a model of heart angiogenesis in vitro
Battegay E., Prof. Dr., Outpatient Department of Internal Medicine and Department of Research, University Hospital Basel, Switzerland
 
75-00Internet laboratory for predicting harmful effects triggered by drugs and chemicals
Vedani A., Prof. Dr., Biographics Laboratory 3R, Basel, Switzerland present address: Department of Chemistry, Molecular Modeling. University of Basel, Pharmacenter, 4056 Basel, Switzerland
 
74-00Validation of polymerase chain reaction assays as replacement of the Mouse Antibody Production (MAP) Test
Bootz F., Dr., Institute of Laboratory Animal Science, University of Zürich, Switzerland
 
73-00Generation and functional characterization of a clonal murine periportal Kupffer cell line from H-2Kb -tsA58 mice
Landmann R., Prof. Dr., Division of Infectious Diseases, Department of Research, University Hospital Basel, Switzerland
 
72-00Development and applications of an in vitro cultivation model for Neospora caninum tissue cyst formation
Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland
 
71-00Detection and characterisation of signs of pain in mice by the combined use of a telemetry model and behavioural observations
Arras M., Dr., Institute of Laboratory Animal Science, University of Zürich, Switzerland
 
70-99Sensory irritant screening using a stable cell line expressing the vanilloid receptor
Baumann T., Prof. Dr., Dept. of Neurological Suregry,Oregon Health and Sciences University, Portland, USA
 
69-99A human neural cell line as in vitro model system for the excitotoxic cascade during stroke
Bicker G., Prof. Dr., Abt. Zellbiologie, Physiologisches Institut, Stiftung Tierärztliche Hochschule Hannover, Germany
 
68-99Genetic analysis of a 3D in vitro model of the rheumatic pannus tissue
Illges H., PD Dr., Biotechnologie Institut Thurgau an der Universität Konstanz, Switzerland
 
67-99Human monocyte-derived dendritic cells as in vitro indicators for contact allergic potential of chemicals
Ulrich P., Dr., PCS/GENEX-Experimental Toxicology, Novartis Pharma AG, Basel, Switzerland
 
66-99The influence of enriched housing conditions on experimental results in laboratory mice
Baumans V., Prof. Dr., Department of Laboratory Animal Science, University of Utrecht, Netherland
 
65-98Reconstructed human epidermis as model for predicting irritancy
Ponec M., Prof. Dr., Skin Research Laboratory, Department of Dermatology, Leiden University Medical Center, Netherland
 
64-97Use of three-dimensional brain cell cultures as a model for ischemia-related research
Honegger P., Prof. Dr., Institute of Physiology, Faculty of Medicine, University of Lausanne, Switzerland
 
63-97In vitro study of pathogenesis of sepsis in a conditionally immortalized Kupffer cell line
Landmann R., Prof. Dr., Division Infectious Deseases, Department Research, University Hospital Basel, Switzerland
 
62-97Development of an in vitro model system for cartilage invasion by synovial fibroblasts
Gay R. E., Prof. Dr., Department of Rheumatology, University Hospital Zürich, Switzerland
 
61-97An in vitro model to study mechanical forces on human venous coronary bypass graft stenosis: Molecular targeting by pharmacological intervention
Lüscher T. F., Prof. Dr., Cardiovascular Research, Institute of Physiology, University Zürich and Cardiology, University Hospital Zürich, Switzerland
 
60-97Transgenic protozoa (Trypanosoma spp.) as an alternative to transgenic animals
Roditi I., Prof. Dr., Institutes of General Microbiology and Parasitology, University of Bern, Switzerland
 
59-97Phenotype characterisation and health monitoring of transgenic mice
Mertens C., dipl. phil. nat., Zürcher Tierschutz (SPCA), Zürich, Switzerland
 
58-97Development of laboratory housing conditions preventing stereotypic behaviour in Mongolian gerbils (Meriones unguiculatus)
König B., Prof. Dr., Department of Animal Behaviour, Institute of Zoology, University of Zürich, Switzerland
 
57-97Laboratory animal husbandry and welfare - Key strategic goals of future research
Würbel H., Prof. Dr., Institute of Animal Sciences, Physiology and Animal Husbandry, Swiss Federal Institute of Technology (ETH), Switzerland
 
56-96Development of a mimotope-based tetanus and diphtheria vaccine
Stadler B. M., Prof. Dr., Institute of Immunology and Allergology, Inselspital, University of Berne, Switzerland
 
55-96Computer-aided identification of ochratoxin antagonists
Vedani A., Prof. Dr., Biographics Laboratory 3R, Basel, Switzerland
 
54-96Elaboration of an in vitro screening method for testing the effect of drugs and other compounds on the renal transport of uric acid
Roch-Ramel F., Prof. Dr., Institute of Pharmacoly and Toxicology, University of Lausanne, Switzerland
 
53-96Axenic cultivation of amastigote forms of Leishmania
Grimm F., Dr. phil. nat., Institute of Parasitology, University of Zürich, Switzerland
 
52-96Development of an interleukin-1 (IL-1) assay with rabbit blood as an alternative to the rabbit pyrogen test
Hartung T., Prof.. Dr., Biochemical Pharmacology, University of Konstanz, Germany
 
51-96Establishment of endotoxin limits in porcine vaccines: animal welfare aspects
Cussler K., Dr., Paul Ehrlich Institut, Langen, Germany
 
50-96Morphometric Analysis of human articular cartilage
Hunziker E., Prof. Dr., M.E.Müller Institut für Biomechanik, University of Bern, Switzerland
 
49-96Cours de formation continue universitaire intitulé “l’utilisation de l’animal en pharmaco/toxicologie et ses alternatives”
Wagnières S., Dr. ès sciences, Service de formation continue, BEB, University of Lausanne, Switzerland
 
48-96Utilization of a model of culture of human intestinal cell lines for the study of the pathogenicity of different strains of Clostridium difficile
Kraehenbuhl J.-P., Prof. Dr., Institut Suisse de Recherches Expérimentales sur le Cancer (ISREC), Switzerland
 
47-96Development of an in vitro system for the detection of estrogenic compounds (xenoestrogens)
Fent K., PD Dr., Swiss Federal Institute for Environmental Science and Technology (EAWAG), Switzerland
 
46-96Development and Validation of an In Vitro Model Simulating Mechanical Ventilation-Induced Inflammation
Pugin J., Dr., Division des Soins Intensifs de Médecine, Hôpital Cantonal Universitaire, Genève, Suisse
 
45-96Replacement of mouse and rat antibody production test by polymerase chain reaction assays
Homberger F., Prof. Dr., Department of Microbiology and Immunology, Weill Medical College of Cornell University and the Memorial Sloaan-Kettering Center, USA
 
44-95Establishment of a micro technique for corticosteroid receptor binding studies
Hügin-Flores M., Dr., Psychopharmacology Unit, Department of Psychiatry, University Hospital, Geneva, Switzerland
 
43-95Short term assay for liver cell activated neurotoxic drugs
Maier P., Prof. Dr., Institute of Toxicology, Swiss Federal Institute of Technology (ETH) and University of Zürich, Switzerland
 
42-92Herstellung von Antikörpern: Einfluss der Adjuvantien auf die Immunantwort und die Belastung der Tiere
Fischer R., Labor für Biochemie I ETH Zürich, Zürich
 
40-92Verwendung von Fischzellkulturen als Testsystem zur Reduktion und zum Ersatz von Tierversuchen in der Oekotoxikologie
Fent K., PD Dr., EAWAG, Dübendorf
 
39-92In vitro Isolation von pathogenen Trypanosomen aus Mensch, Haustier und Tsetsefliege
Brun R., Kaminsky R., PD Dr. PD Dr., Schweizerisches Tropeninstitut, Basel
 
38-92CO2-Anästhesie beim Labortier
Schatzmann U., Prof. Dr., Institut für Nutztiere und Pferde Universität Bern, Bern
 
37-92Nachweis von Clostridien-Toxinen ohne Tierversuch
Nicolet J., Prof. Dr., Institut für Veterinärbakteriologie Universität Bern, Bern
 
36-92Ersatz tierischer Antikörper durch rekombinante antikörper-präsentierende Bakteriophagen
Seebeck T., Prof. Dr., Institut für Allgemeine Mikrobiologie Universität Bern, Bern
 
35-92Nouvelle méthode de quantification de toxicité in vitro basée sur la modification de stress cellulaire
Kolakofski D., Prof. PhD, Institut de Génétique et Microbiologie CMU Centre Médical Universitaire, Genève
 
34-92Validierungsstudie zur tierfreien in vitro Produktion von monoklonalen Antikörpern zusammen mit 31 Teilprojektteilnehmern
Stiftung Forschung 3R, Stiftung Forschung 3R, Münsingen
 
33-92Nachweis karzinogenese-relevanter Punktmutationen
Lüthi J., Wegmüller B., PD Dr. Dr., Institut für Biochemie Universität Bern, Bern
 
32-92A new model for in vitro corneal epithelial wound healing study
Böhnke M., Prof. Dr., Universitäts Augenklinik Inselspital, Bern
 
30-92Toxikologische Untersuchung der Blutbildung in vitro
Ryffel B., Dr., vormals Institut für Toxikologie der ETH und Universität Zürich, Scherzenbach
 
29-92Corticotrophin (ACTH) -Bestimmung in Arzneimitteln
Weyers W., Fachapotheker, CONFARMA AG, Münchenstein, Schweiz
 
28-92Analysis of the applicability of in vitro immunological methodologies to the study of foot-and-mouth disease vaccine efficacy
McCullough K. Ch., Dr., Institut für Viruskrankheiten und Immunprophylaxe, IVI, Mittelhäusern
 
27-92Entwicklung und Evaluation von Methoden zum Erfassen pyrogener Substanzen
Jungi T. W., Prof. Dr., Institut für Veterinär-Virologie Universität Bern, Bern
 
26-92Produktion von monoklonalen Antikörpern mittels Repertoire Cloning
Stadler B. M., Prof. Dr., Institut für Immunologie und Allergologie Inselspital, Bern
 
25-92Organotypic cultures: A model for pharmacological analysis in the central nervous system
Muller D., Dr. med., Pharmacologie CMU Centre Médical Universitaire, Genève
 
24-91Nachweismethoden für enteropathogene E. coli (EPEC) beim Kalb
Pospischil A., Prof. Dr., Institut für Veterinärpathologie Universität Zürich, Zürich
 
23-91Anästhesiemöglichkeiten bei der Ratte
Becker M., PD Dr. med. vet., Kantonales Veterinäramt Basel Stadt Abteilung Tierschutz, Basel
 
22-91Screening Methode zur Abklärung des Abbaus von Cholesterin in vitro
Niésor E., Dr., Symphar SA, Versoix
 
21-91In vitro Herstellung von mAK mit Bioreaktoren II
Fischer R., Labor für Biochemie I ETH Zürich, Zürich
 
20-90Verwendung eines menschlichen Darmzellkulturmodelles zur Reduktion und zum Ersatz von Tierversuchen auf dem Gebiet der Verdauungsphysiologie
Hauri H. P., Prof. Dr., Abteilung Pharmakologie Biozentrum Universität Basel, Basel
 
19-90Remplacement des animaux dans les études sur Toxoplasma gondii II
Pechère J. - C., Prof. Dr., Microbiologie CMU Centre Médical Universitaire, Genève
 
18-90In vitro Herstellung von mAK mit Bioreaktoren I
Fischer R., Institut für Biochemie ETH Zürich, Zürich
 
17-90Einführung des Cell-Pharm für die mAK-Produktion
Hübscher U., Prof. Dr., Institut für Pharmakologie und Biochemie Universität Zürich, Zürich
 
16-89Produktionseinheit zur Produktion von mAK
Zinkernagel R., Prof. Dr., Institut für exp. Immunologie Universitätsspital Zürich, Zürich
 
15-88Validation of three in vitro toxicity / teratogenicity test systems using identical coded compounds (together with Swiss NSFP 17)
Kucera P., Prof. Dr., Institut de Physiologie Université de Lausanne, Lausanne
 
13-88Endothelzellkulturen auf Cytodex-Microcarrier: Adhärenzmessung von neutrophilen Granulozyten in einem physiologischen System
Zwahlen R., PD Dr. med. vet., Sektion Blutprodukte Bundesamt für Gesundheitswesen, Bern
 
12-88DNA-Replikationssystem zur tierfreien Wirkungs- und Toxizitäts-Testung
Neftel K., Prof. Dr., Ziegler Spital, Bern
 
11-88Tierschutzgerechte Euthanasie von Labortieren
Schatzmann U., Prof. Dr., Institut für Nutztiere und Pferde Universität Bern, Bern
 
10-88Entwicklung eines künstlichen Fütterungssystems zur Zucht von Schildzecken
Diehl P. A., Guerin P., Prof. Dr. Dr., Institut de Zoologie Université de Neuchâtel, Neuchâtel
 
09-88In vitro Bestimmung schutzinduzierender Antigene in der Tollwutdiagnostik
Bruckner L., Dr. med. vet., Institut für Viruskrankheiten und Immunprophylaxe, IVI, Mittelhäusern
 
08-88Remplacement des animaux dans les études sur Toxoplasma gondii I
Pechère J.- C., Prof. Dr., Microbiologie CMU Centre Médical Universitaire, Genève
 
07-88Erregungsleitung und Transporteigenschaften in Nerven und Epithelien
Durand J., Prof. Dr., Institut de Physiologie Université de Fribourg, Fribourg
 
06-88Tierschonender Einsatz des Beagle Hundes in der Toxikologie
Zbinden G., Prof. em. Dr. (verst.), Institut für Toxikologie der ETH und Universität Zürich, Zürich
 
05-87Kältekonservierung von Wurmparasiten
Eckert J., Prof. em. Dr., Institut für Parasitologie Universität Zürich, Zürich
 
04-87Erkennung erbschädigender Substanzen an der Taufliege Drosophila
Würgler F., Prof. em. Dr., Institut für Toxikologie der ETH und Universität Zürich, Zürich
 
03-87In vitro Test zum Nachweis des LCM-Virus
Zinkernagel R., Prof. Dr., Institut für exp. Immunologie Universitätsspital Zürich, Zürich
 
02-87Menschliches Lebergewebe als Ersatz des Tierversuchs bei der Arzneimittelprüfung
Meyer U. A., Prof. Dr., Biozentrum Universität Basel, Basel
 
01-87Verminderung von Tierversuchen in der Tollwut-Diagnostik durch Verbesserung der in vitro Diagnostik-Methoden
Peterhans E., Prof. Dr., Institut für Veterinär-Virologie Universität Bern, Bern
 


TOP